Dashboard
Manage Tickers

COYACoya Therapeutics, Inc.

Nasdaq coyatherapeutics.com


$ 7.26 $ -0.58 (-7.46 %)    

Friday, 14-Jun-2024 15:58:38 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 7.2
$ 7.64
$ 7.31 x 100
$ 0.00 x 0
$ 7.17 - $ 7.64
$ 3.21 - $ 10.69
101,247
na
21.96M
$ 0.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rodman--renshaw-initiates-coverage-on-coya-therapeutics-with-buy-rating-announces-price-target-of-18
Rodman & Renshaw Initiates Coverage On Coy...
06/13/2024 17:31:23

Rodman & Renshaw analyst Elemer Piros initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announ...

coya-therapeutics-announces-publication-of-phase-1-study-on-ctla4-ig-and-interleukin-2-combination-therapy-for-als-in-frontiers-in-neurology
Coya Therapeutics Announces Publication Of...
06/11/2024 12:16:07

Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) an...

coya-therapeutics-peer-reviewed-manuscript-titled-a-phase-1-proof-of-concept-study-evaluating-safety-tolerability-and-biological-marker-responses-with-combination-therapy-of-ctla4-ig-and-interleukin-2-in-amyotrophic-lateral-sclerosis-accepted-in-medical-journal-frontiers-in-neurology
Coya Therapeutics Peer-Reviewed Manuscript...
06/03/2024 12:18:42

coya-therapeutics-announces-inclusion-in-msci-usa-micro-cap-index-at-mkt-close-may-31
Coya Therapeutics Announces Inclusion In M...
05/28/2024 12:18:17

coya-therapeutics-completes-controlled-phase-2-study-of-low-dose-interleukin-2-in-patients-with-alzheimers-disease
Coya Therapeutics Completes Controlled Pha...
05/22/2024 12:16:23

This investigator-initiated, double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer's Associa...

coya-therapeutics-announces-the-alzheimers-drug-discovery-foundation-has-purchased-603136-shares-of-cos-stock-at-829-per-share
Coya Therapeutics Announces The Alzheimer'...
05/20/2024 12:16:16

coya-therapeutics-q1-2024-gaap-eps-035-misses-030-estimate
Coya Therapeutics Q1 2024 GAAP EPS $(0.35)...
05/09/2024 21:37:18

Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $...

chardan-capital-maintains-buy-on-coya-therapeutics-maintains-14-price-target
Chardan Capital Maintains Buy on Coya Ther...
04/29/2024 12:05:15

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.

chardan-capital-maintains-buy-on-coya-therapeutics-raises-price-target-to-14
Chardan Capital Maintains Buy on Coya Ther...
03/20/2024 09:31:07

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and raises the price target from $11...

coya-therapeutics-fy23-eps-079-vs-473-yoy-collaboration-revenue-of-6m
Coya Therapeutics FY23 EPS $(0.79) Vs $(4....
03/19/2024 12:19:23

Financial Results As of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5...

coya-therapeutics-presents-biomarker-data-on-neuroinflammatory-pathways-in-frontotemporal-dementia-at-the-adpd-2024-conference
Coya Therapeutics Presents Biomarker Data ...
03/06/2024 13:17:03

Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines signific...

coya-therapeutics-to-present-data-on-immune-system-and-regulatory-t-cell-contributions-in-frontotemporal-dementia-patients-at-adpd-2024-conference
Coya Therapeutics To Present Data On Immun...
02/29/2024 13:51:50

Company to present comprehensive analysis documenting pro-inflammatory cell phenotypes and Treg dysfunction in FTD patients vs....

coya-therapeutics-to-present-novel-biomarker-survival-data-in-large-cohort-of-als-patients-at-society-of-neuroimmune-pharmacology-conference
Coya Therapeutics To Present Novel Biomark...
02/22/2024 13:29:32

Novel biomarker data in ALS patients correlates to rate of progression and survivalCoya Therapeutics, Inc. (NASDAQ:COYA) ("...

coya-therapeutics-issues-letter-to-stockholders-highlighting-expansion-of-coya-302-into-alzheimers-disease-and-coyas-pathway-to-a-pipeline-in-a-product
Coya Therapeutics Issues Letter To Stockho...
02/21/2024 13:32:29

Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways i...

greenlight-capital-adds-position-in-coya-therapeutics-with-834k-share-stake
Greenlight Capital Adds Position In Coya T...
02/14/2024 22:13:16

coya-therapeutics-licenses-ip-rights-for-immune-modulatory-biologics-in-combination-with-coya-301-to-enhance-regulatory-t-cells-in-inflammatory-diseases
Coya Therapeutics Licenses IP Rights For I...
02/13/2024 13:21:16

License from University of Nebraska Medical Center covers multiple low dose interleukin-2 (ld IL-2) combinations, including ld ...

coya-therapeutics-announces-pipeline-expansion-of-coya-302-to-include-frontotemporal-dementia-and-parkinsons-disease
Coya Therapeutics Announces Pipeline Expan...
01/16/2024 13:27:00

All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dys...

coya-therapeutics-reveals-successful-pre-ind-and-type-c-meetings-with-fda-to-advance-development-of-coya-302-for-treatment-of-amyotrophic-lateral-sclerosis-als
Coya Therapeutics Reveals Successful Pre-I...
01/05/2024 13:05:09

coya-therapeutics-ceo-dr-howard-berman-issues-letter-to-stockholders
Coya Therapeutics' CEO Dr. Howard Berman I...
12/13/2023 13:17:01

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company develop...

coya-therapeutics-shares-resume-trade
Coya Therapeutics Shares Resume Trade
12/06/2023 12:36:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)